|Mr. Armando Anido MBA||Chairman & CEO||993.36k||N/A||1958|
|Ms. Terri B. Sebree||Pres||764.03k||N/A||1958|
|Mr. James E. Fickenscher||CFO & VP of Corp. Devel.||608.02k||N/A||1964|
|Mr. Albert P. Parker II||Chief Legal Officer & Corp. Sec.||N/A||N/A||1966|
|Mr. Joseph Apostolico||VP of HR||N/A||N/A||N/A|
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Zynerba Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.